A novel Candida albicans skin test antigen: efficacy and safety in man

Abstract

Yeast phase Candida albicans (ATCC No. 10231) was grown in a nonantigenic medium, harvested and lyophilized. Ammonium sulfate fractions of an aqueous extract of the lyophilized cells were evaluated and the fraction yielding the highest specific delayed cutaneous reactivity in sensitized guinea-pigs was used to prepare a C. albicans skin test antigen (CASTA). The safety of the antigen was evaluated by measuring immediate and delayed (0·25, 6, 24, 48 and 72 h) cutaneous reactions in atopic and nonatopic human subjects. The outcome of three repetitive monthly Mantoux skin tests with 0·01-1 μg antigen doses was used to test for booster effects in 14 subjects and to estimate a safe initial test antigen dose. The utility of a single skin test as a measure of cell-mediated immunity was evaluated in 40 healthy subjects. Reactor rates (≥2 mm, 48 h) of 40% and 85% were detected, respectively, with doses of 0·0316 and 1 μg. Using a skin test reaction diameter ≥5 mm at 48 h, the reactor rate was 50% for the 1-μg dose. The only adverse reaction (45 mm, 0·25 h) was detected with the 1-μg dose in an atopic subject who also exhibited exquisite scratch test reaginic hypersensitivity to C. albicans allergen. The prevalence of other adverse reactions to this antigen compared favorably with that to other antigens used for recall antigen testing. These studies suggest the 1-μg CASTA dose can be used for effective, safe recall antigen skin tests.